Literature DB >> 32111231

NoncoRNA: a database of experimentally supported non-coding RNAs and drug targets in cancer.

Lulu Li1, Pengfei Wu1, Zhenyu Wang1, Xiangqi Meng1, Caijun Zha2, Ziwei Li1, Tengfei Qi1, Yangong Zhang1, Bo Han1,3, Shupeng Li1, Chuanlu Jiang4, Zheng Zhao5, Jinquan Cai6.   

Abstract

NoncoRNA (http://www.ncdtcdb.cn:8080/NoncoRNA/) is a manually curated database of experimentally supported non-coding RNAs (ncRNAs) and drug target associations that aim to potentially provide a high-quality data resource for exploring drug sensitivity/resistance-related ncRNAs in various human cancers. ncRNA are RNA molecular that do not encode proteins, but are involved in gene regulation and cellular functions in variety of human diseases, including neurodegenerative diseases and cancers. Here, we developed NoncoRNA which contained 8233 entries between 5568 ncRNAs and 154 drugs in 134 cancers. Each entry in the NoncoRNA contains detailed information on the ncRNAs, drugs, and cancers, the ncRNA expression pattern and experimental detection techniques, drug response and other targets, literature references, and other information. NoncoRNA offers a user-friendly, open access web interface to easily browse, search, and download data. NoncoRNA also provides a submission page for researchers to submit newly validated ncRNA-drug-cancer associations. NoncoRNA might serve as an immeasurable resource for understanding the roles of ncRNAs in cancer therapy.

Entities:  

Keywords:  Database; Drug resistance; Human cancer; Non-coding RNA

Mesh:

Substances:

Year:  2020        PMID: 32111231      PMCID: PMC7048090          DOI: 10.1186/s13045-020-00849-7

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


To the Editor, Cancer is an important cause of morbidity and mortality worldwide, in every world region, and irrespective of the level of human development [1]. In addition, the incidence and mortality of cancer have increased rapidly worldwide in recent years. The reasons are complex, but drug resistance is the primary cause of clinical treatment failure [2]. However, the mechanism of drug resistance to chemotherapeutic agents is not fully elucidated. Currently, more and more evidences have been proved that non-coding RNAs play critical roles in drug resistance [3-6]. ncRNAs including long non-coding RNAs (lncRNAs), microRNAs (miRNAs), circular RNAs (circRNAs), and PIWI-interacting RNAs (piRNAs) are suggested to be the potential promising therapeutic targets for overcoming drug resistance in the treatment of human cancers [7-10]. Due to their functional importance, ncRNAs are under intense study at present, and some databases have been built to describe ncRNAs’ functional characterization, such as ncDR, Lnc2Cancer, SM2miR, CircR2Disease, and piRBase. Current ncRNA research related to drug resistance is mainly focused on lncRNAs and miRNAs. However, few studies have reported the association between circRNAs and piRNAs. Therefore, it is urgent demand to establish a database for more comprehensive data coverage drug resistance and ncRNAs in human cancers. To fill this gap, we introduced NoncoRNA, a manually curated database of experimentally supported non-coding RNA and drug target associations in cancers. The current version contains 8233 entries involved in 5568 ncRNAs and 154 drugs in 134 cancers (Table 1). In addition, we also summarized the key ncRNAs of most common 10 drugs and the cancers associated ncRNAs in Additional file 1: Table S1 and S2.
Table 1

Data summary in NoncoRNA database

FeaturesNoncoRNA
Entries8233
LncRNAs3599
miRNAs1006
circRNAs959
piRNAs4
Cancer subtypes134
Drugs154
Target gene721
Pathways340
Articles1615
Data summary in NoncoRNA database To establish a high-quality database of ncRNAs, all the articles related to drug resistance and ncRNAs were manually extracted from publications (Fig. 1). (i) We searched all published studies in the PubMed database using the following combination of keywords: “long non-coding RNA or lncRNA and drug and cancer,” “microRNA or miRNA and drug and cancer,” “circRNA and drug and cancer,” and “piRNA or PIWI-interacting RNA and drug and cancer.” Besides, we also integrated relevant information from ncDR and Lnc2Cancer. Then, we manually retrieved entries related to ncRNAs, drugs, and cancers by reading abstracts. (ii) The abstract and the full text of selected articles were manually screened to extract drug resistance-related ncRNAs and their detailed annotation information, such as article’s basic information, ncRNAs’ basic information, drug basic information, and the relationship between ncRNAs and drugs. The relationship between ncRNAs and drugs in cancers were supported by experiment, such as qRT-PCR, southern-blot, and high-throughput experiment. Similarly, we have provided experimental data related to ncRNAs and drug resistance in our laboratory, such as lnc-ERC1-1:5, lnc-SCG3-3:3, and NR_028415. (iii) In order to share information among different databases, we unified the information by certain criteria, including the drug ID from DrugBank and ncRNA ID from Ensembl, miRBase, circBase, piRBase, and so on. Then Disease Ontology and DrugBank were used to respectively unify cancer and drug annotations.
Fig. 1

The workflow of the construction of NoncoRNA database

The workflow of the construction of NoncoRNA database NoncoRNA offers a user-friendly, open access web interface to easily browse, search, and download data. Figure 1 shows the schematic workflow of NoncoRNA database. In the “search” page, users can search all entries in three ways: by ncRNAs, by drugs, or by cancers. In the “browse” page, users can browse by clicking “ncRNAs”, “drugs”, or “cancer type” according to their purpose, the information would be listed as leaf nodes. In addition, the NoncoRNA also provides “quick search” function in the home page and search interface, such as miR-200, glioma, and temozolomide. Through clicking “more”, you can obtain detailed information. Figure 1 shows the more details, the entry contains detailed information on the ncRNAs, drugs, and cancers, the ncRNA expression pattern and experimental detection techniques, drug response, target gene, pathways, literature references, and other information. In addition, all data in the database can be obtained by the function of download. The NoncoRNA provides two formats of the downloadable file in TXT and Excel formats, respectively. The submit function enables communication between users and websites. Users enable to submit novel experimentally supported ncRNA-drug-cancer association. The help function can teach users how to use NoncoRNA. In addition, the web proved some query examples, it also helps users better understand how to use NoncoRNA. In conclusion, NoncoRNA may serve as an immeasurable source for drug resistance research in human cancer. Compared with other databases, the NoncoRNA includes 3 distinctive features: (i) first providing the relationship between circRNAs, piRNAs, and drug resistance in cancers; (ii) 3294 lncRNAs were provided from our laboratory database by microarray analysis, which has not been studied in the field of gliomas; (iii) exhibiting some relationship between ncRNAs and drug resistance in cancer. Meanwhile, we will update and improve the database every 2 months. So we can use this relationship to develop the function of ncRNA in different cancers and drugs, and even to predict the new function in other cancers and drugs. Anyway, NoncoRNA provides a reliable database platform for a wide range of scientific researchers. Additional file 1: Table S1. Summary of the top 5 ncRNAs with references for most common 10 drugs. Table S2. Summary of cancers associated with ncRNAs.
  10 in total

Review 1.  Implication of microRNAs in drug resistance for designing novel cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong; Shadan Ali
Journal:  Drug Resist Updat       Date:  2010-03-17       Impact factor: 18.500

2.  circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer.

Authors:  Yuting Sang; Bing Chen; Xiaojin Song; Yaming Li; Yiran Liang; Dianwen Han; Ning Zhang; Hanwen Zhang; Ying Liu; Tong Chen; Chen Li; Lijuan Wang; Wenjing Zhao; Qifeng Yang
Journal:  Mol Ther       Date:  2019-05-17       Impact factor: 11.454

3.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 4.  Cancer drug resistance: an evolving paradigm.

Authors:  Caitriona Holohan; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 5.  Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer.

Authors:  Ehsan Malek; Sajjeev Jagannathan; James J Driscoll
Journal:  Oncotarget       Date:  2014-09-30

Review 6.  Long non-coding RNAs in hematological malignancies: translating basic techniques into diagnostic and therapeutic strategies.

Authors:  Nonthaphat Kent Wong; Chien-Ling Huang; Rashidul Islam; Shea Ping Yip
Journal:  J Hematol Oncol       Date:  2018-11-22       Impact factor: 17.388

7.  PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma.

Authors:  Dongmei Mai; Peirong Ding; Liping Tan; Jialiang Zhang; Zhizhong Pan; Ruihong Bai; Cong Li; Mei Li; Yifeng Zhou; Wen Tan; Zhixiang Zhou; Yexiong Li; Aiping Zhou; Ying Ye; Ling Pan; Yanfen Zheng; Jiachun Su; Zhixiang Zuo; Zexian Liu; Qi Zhao; Xiaoxing Li; Xudong Huang; Wei Li; Siqi Wu; Weihua Jia; Shuangmei Zou; Chen Wu; Rui-Hua Xu; Jian Zheng; Dongxin Lin
Journal:  Theranostics       Date:  2018-10-06       Impact factor: 11.556

Review 8.  Noncoding RNAs in cancer therapy resistance and targeted drug development.

Authors:  Wen-Tao Wang; Cai Han; Yu-Meng Sun; Tian-Qi Chen; Yue-Qin Chen
Journal:  J Hematol Oncol       Date:  2019-06-07       Impact factor: 17.388

9.  miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells.

Authors:  Mads Heilskov Rasmussen; Iben Lyskjær; Rosa Rakownikow Jersie-Christensen; Line Schmidt Tarpgaard; Bjarke Primdal-Bengtson; Morten Muhlig Nielsen; Jakob Skou Pedersen; Tine Plato Hansen; Flemming Hansen; Jesper Velgaard Olsen; Per Pfeiffer; Torben Falck Ørntoft; Claus Lindbjerg Andersen
Journal:  Nat Commun       Date:  2016-08-16       Impact factor: 14.919

10.  Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p.

Authors:  Pengfei Wu; Jinquan Cai; Qun Chen; Bo Han; Xiangqi Meng; Yansheng Li; Ziwei Li; Ruijia Wang; Lin Lin; Chunbin Duan; Chunsheng Kang; Chuanlu Jiang
Journal:  Nat Commun       Date:  2019-05-03       Impact factor: 14.919

  10 in total
  15 in total

1.  LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.

Authors:  Chixing Luo; Chuansheng Nie; Yibin Zeng; Kang Qian; Xudong Li; Xuan Wang
Journal:  Mol Neurobiol       Date:  2022-04-14       Impact factor: 5.590

2.  RNAInter v4.0: RNA interactome repository with redefined confidence scoring system and improved accessibility.

Authors:  Juanjuan Kang; Qiang Tang; Jun He; Le Li; Nianling Yang; Shuiyan Yu; Mengyao Wang; Yuchen Zhang; Jiahao Lin; Tianyu Cui; Yongfei Hu; Puwen Tan; Jun Cheng; Hailong Zheng; Dong Wang; Xi Su; Wei Chen; Yan Huang
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

3.  Baohuoside I via mTOR Apoptotic Signaling to Inhibit Glioma Cell Growth.

Authors:  Yangyang Guo; Cheng Wang; Minghui Jiang; Hengyue Zhu; Min Weng; Linxiao Sun; Yanlei Zhang
Journal:  Cancer Manag Res       Date:  2020-11-10       Impact factor: 3.989

4.  ViRBase v3.0: a virus and host ncRNA-associated interaction repository with increased coverage and annotation.

Authors:  Jun Cheng; Yunqing Lin; Linfu Xu; Kechen Chen; Qi Li; Kaixin Xu; Lin Ning; Juanjuan Kang; Tianyu Cui; Yan Huang; Xiaoyang Zhao; Dong Wang; Yanhui Li; Xi Su; Bin Yang
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

5.  Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.

Authors:  Wahafu Alafate; Dongze Xu; Wei Wu; Jianyang Xiang; Xudong Ma; Wanfu Xie; Xiaobin Bai; Maode Wang; Jia Wang
Journal:  J Exp Clin Cancer Res       Date:  2020-11-11

Review 6.  The functions and clinical significance of circRNAs in hematological malignancies.

Authors:  Xiangxiang Zhou; Linquan Zhan; Kai Huang; Xin Wang
Journal:  J Hematol Oncol       Date:  2020-10-17       Impact factor: 17.388

7.  Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma.

Authors:  Ruichao Chai; Guanzhang Li; Yuqing Liu; Kenan Zhang; Zheng Zhao; Fan Wu; Yuzhou Chang; Bo Pang; Jingjun Li; Yangfang Li; Tao Jiang; Yongzhi Wang
Journal:  Cancer Biol Med       Date:  2021-02-15       Impact factor: 4.248

Review 8.  EMT-associated microRNAs and their roles in cancer stemness and drug resistance.

Authors:  Guangtao Pan; Yuhan Liu; Luorui Shang; Fangyuan Zhou; Shenglan Yang
Journal:  Cancer Commun (Lond)       Date:  2021-01-27

Review 9.  DNA Damage Repair in Brain Tumor Immunotherapy.

Authors:  Shihong Zhao; Boya Xu; Wenbin Ma; Hao Chen; Chuanlu Jiang; Jinquan Cai; Xiangqi Meng
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

10.  LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway.

Authors:  Maolin Mu; Wanxiang Niu; Xiaoming Zhang; Shanshan Hu; Chaoshi Niu
Journal:  Oncogene       Date:  2020-09-25       Impact factor: 8.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.